Table 4.
Validation of the PMcardio app for secondary outcomes in the overall sample (n = 290)
| Significant ST deviation | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ref + | Ref - | Sensitivity | Specificity | LR+ | LR- | PPV | NPV | Kappa† | ||
| PMcardio | + | 8 | 16 | 66.7% (34.9–90.1) | 94.2% (90.8–96.7) | 11.5 (6.2–21.5) | 0.35 (0.16–0.79) | 33.3% (21.2–48.2) | 98.5% (96.7–99.3) | 0.91 (0.81–1.00) |
| - | 4 | 261 | ||||||||
| Left ventricular hypertrophy | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ref + | Ref - | Sensitivity | Specificity | LR+ | LR- | PPV | NPV | Kappa† | ||
| PMcardio | + | 7 | 42 | 63.6% (30.7–89.1) | 84.9% (80.1–88.9) | 4.2 (2.5–7.1) | 0.43 (0.2–0.9) | 14.3% (9.0–22.0) | 98.3% (96.4–99.2) | 0.83 (0.74–0.91) |
| - | 4 | 236 | ||||||||
| Ectopy | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ref + | Ref - | Sensitivity | Specificity | LR+ | LR- | PPV | NPV | Kappa† | ||
| PMcardio | + | 25 | 30 | 89.3% (71.8–97.7) | 88.5% (84.0–92.1) | 7.8 (5.4–11.1) | 0.12 (0.04–0.35) | 45.5% (36.8–54.4) | 98.7% (96.4–99.6) | 0.86 (0.79–0.94) |
| - | 3 | 231 | ||||||||
| Any BBB | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ref + | Ref - | Sensitivity | Specificity | LR+ | LR- | PPV | NPV | Kappa† | ||
| PMcardio | + | 23 | 8 | 92.0% (74.0–99.0) | 97.0% (94.1–98.7) | 30.4 (15.2–60.7) | 0.08 (0.02–0.31) | 74.2% (59.0–85.2) | 99.2% (97.1–99.8) | 0.93 (0.85–1.00) |
| - | 2 | 256 | ||||||||
Data are point estimate (95% confidence interval). Reference in each analysis is expert panel consensus on presence of the outcome of interest.
BBB = bundle branch block; LR+ = positive likelihood ratio; LR- = negative likelihood ratio; NPV = negative predictive value; PPV = positive predictive value.
†
Kappa for interobserver agreement between Android and iPhone.